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ment with BOT might be related to beneﬁts for the patients as
well as for the health care system.
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OBJECTIVES: To assess the treatment compliance and illness
knowledge of diabetic patients and to and to study its possible
relation to patient’s glycemic control. METHODS: An epide-
miological, cross sectional, naturalistic study was carried out in
Spanish Primary Care centres. Patients >18 years with diabetes
mellitus type 1 (T1DM) or type 2, with insulin treatment
(T2DM-i) or not (T2DM-n.i), were enrolled in the study (con-
secutive cases sampling). The last value of glycosylated hemo-
globin (HbA1c) of each patient, reported in 2006, deﬁned the
glycemic control as satisfactory (HbA1c  7%) or unsatisfac-
tory (HbA1c > 7%). Treatment compliance was obtained from
Morisky Green questionnaire (MG) and illness knowledge from
6 questions about diabetes. RESULTS: A total of 679 patients
were enrolled in the study: 52.4% female; age 65.2 (13.7); BMI
28.81 (4.66); type of diabetes: 11.5% T1DM, 26.2% T2DM-i
and 62.3% T2DM-n.i; mean time from diagnoses 11.9 (9.25)
years. 53% of patients achieved satisfactory control (T1DM:
29.5%, T2DM-i: 31.5% and T2DM-n.i: 63.8%; p < 0.001). A
total of 67.4% of patients presented a good compliance accord-
ing to MG scores; no signiﬁcant differences were found
between glycemic control groups or type of diabetic patients.
99.0% of patients knew they had diabetes or that they were
taking drugs for it, 33.2% knew what HbA1c means, 22.7%
knew their last HbA1c value and 21.4% knew the appropriate
HbA1c value; unsatisfactory glycemic control group demon-
strated better knowledge in relation to these 3 questions
(p < 0.05). 81.6% of diabetic patients with high blood pressure
(N = 516) and 79.9% of patients with high cholesterol levels
(N = 488) were aware of having these levels above appropriate
values; no signiﬁcant differences were found between glycemic
control groups or type of diabetes in these two questions.
CONCLUSIONS: This study shows that percentage of patients
with a good compliance and knowledge about their illness
should increase. More efforts should be done in these areas to
improve treatment effectiveness.
PDB45
SELF-MANAGEMENT AND PATIENT PERCEPTIONS OF CARE
IN RELATIONTO HEALTH AND COST-RELATED OUTCOMES
INTYPE 2 DIABETES: A SYSTEMATIC REVIEW
Cobden D1, Niessen L2, Rutten F3, Redekop WK2
1Roche Inc, Nutley, NJ, USA, 2Erasmus Medical Center, Rotterdam,The
Netherlands, 3IMTA, Rotterdam,The Netherlands
OBJECTIVES: During its long course, Type 2 diabetes treatment
involves complex interactions between patient-related non-
biological and biological factors. A better understanding of these
interactions is likely to strengthen efforts to reduce the health and
economic burden of diabetes. We reviewed the literature regard-
ing the relationships between patient-related factors, treatment
outcomes, and standard economic parameters that are part of
informed medical decision-making. METHODS: A systematic
literature review was performed on articles dated 1993–2007
employing comprehensive medical subject heading (MeSH) and
keyword searches in electronic reference libraries. Content
matter and formatting criteria were pre-deﬁned. Inclusion crite-
ria were: 1) sole/predominant focus on T2D; 2) correlative analy-
sis of at least 2 relevant parameters (self-management, treatment
changes, patient-reported outcomes, clinical outcomes, and cost-
related outcomes); and 3) use of questionnaires to capture
patient-reported outcomes. Standardized data collection and
abstracting techniques were followed according to Cochrane
methodologies. RESULTS: A total of 110 manuscripts were
retrieved, with 67 fulﬁlling all inclusion criteria. Most studies
were retrospective (37/67; 55%) and from managed care settings
(84%). Oral anti-diabetic drugs were a central focus, appearing
in >90% of studies. Patient-related non-biological factors of care,
particularly medication adherence and persistence, are well-
researched (n = 52) and shown to inﬂuence diabetes outcomes
(eg, HbA1c and major hypoglycemia), cardiovascular risk, and
mortality rates, as well as treatment-speciﬁc resource use (eg,
hospitalization rates) and costs (by up to $3400 annually per
patient). Patient satisfaction and wellbeing were also strongly
associated with diabetes treatment outcomes. CONCLUSIONS:
Robust correlations exist between self-management, treatment
satisfaction/preferences, psychological wellbeing, and clinical
outcomes in Type 2 diabetes. These interactions may signiﬁcantly
affect health and cost-related outcomes as well. Further research
on the health economic impact of non-biological factors of care
is warranted and would improve value-based resource allocation
and appropriate access to care.
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OBJECTIVES: To characterize, in diabetic patients, the preva-
lence of complications of the disease, the frequency of self-
monitoring, and to explore the relationship between these
aspects and patient’s health related quality of life (HRQoL).
METHODS: Diabetic patients were recruited through commu-
nity pharmacies, in a descriptive national cross-sectional study.
Two structured questionnaires were used to collect patients’ data.
One, administered by the pharmacist, to characterize patients’
complications and self-monitoring of the disease, and a second
one, a self-administered diabetes-speciﬁc quality of life
questionnaire—“Audit of Diabetes Dependent Quality of Life
(ADDQoL)” (Portuguese version 6.6.02). ADDQoL has 2
general items (current HRQoL and overall impact of diabetes on
the HRQoL and 18 speciﬁc items. Statistical analysis (package
SAS), included 95% conﬁdence intervals for average weighted
impact score estimates. A generalized linear model (GLM) was
performed to assess the relationship between QoL and the other
variables involved. RESULTS: A total of 1479 diabetic patients
were involved, 53.7% females, mean age 64.1 years old, 19%
with BMI less than 25 kg/m2. A total of 73% patients reported
doing glucose self-monitoring at least twice a month. Self-
monitoring of feet, weight and blood pressure was never done by
30%, 14% and 7%, respectively. A total of 80.2% of all patients
reported using oral hypoglycaemic drugs only, 10.4% only
insulin and 9.4% combined therapy (oral antidiabetic drugs and
insulin) The ADDQoL AWI score showed a negative impact of
diabetes in QoL (CI 95%: -1.96–-1.79). The GLM Model
showed that BMI, education level, insulin dependency, self-
monitoring of glycaemia, retinopathy and neuropathy were asso-
ciated with patients’ AWI score. CONCLUSIONS: Although
glucose self-monitoring was done by the majority of the patients,
monitoring for diabetes complications is still far from ideal. As
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expected, diabetes has a negative impact on diabetic patient’s
quality of life, some variables were identiﬁed to contribute to a
worst perceived QoL.
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OBJECTIVES: Previous research has shown that generic
patient-reported outcome (PRO) measures underestimate the
impact of polycystic ovary syndrome (PCOS) on quality of life
(QoL). Following recent regulatory guidance, our review aimed
to identify PCOS-speciﬁc QoL measures and establish whether
their development history and measurement properties support
their use in clinical trials. METHODS: A systematic search of
MEDLINE and PsycINFO was conducted using terms synony-
mous with “PCOS” in combination with terms associated with
“QoL” to identify PCOS-speciﬁc QoL measures completed by
the patient. Articles were included if written in the English lan-
guage and published since 1998. Following identiﬁcation of
measures, further searches were undertaken using the question-
naire name and abbreviation to explore its use, development
history and demonstrated measurement properties. RESULTS:
Sixty-ﬁve abstracts were identiﬁed and screened. Of these, 19
reported quantitative studies using a variety of PRO question-
naires (most commonly the SF-36). Only one PCOS-speciﬁc
QoL questionnaire was identiﬁed: the PolyCystic Ovary Syn-
drome Questionnaire (PCOSQ). A search for use of the PCOSQ
since its development publication (1998) returned ten papers,
which were included in our review. The PCOSQ’s development
history (including conceptual and endpoint models) is inad-
equate, with recent studies indicating that the PCOSQ does not
have good content validity, e.g. the impact of acne on QoL is
notably missing. The PCOSQ subscales demonstrate acceptable
levels of reliability (0.54–0.93) and partial known-groups valid-
ity (p < 0.05 between treatment and placebo groups on three of
the ﬁve PCOSQ domains) as well as convergent/divergent valid-
ity with other PRO instruments. Responsiveness to change has
been variable and minimally important differences (MIDs) have
not been established. CONCLUSIONS: The PCOSQ has domi-
nated research relating to the impact of PCOS on QoL.
However, in order to fulﬁl current regulatory requirements,
additional research is required to ensure its comprehensibility
and sensitivity prior to including the PCOSQ in a clinical trial
programme.
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OBJECTIVES: Quality of life (QoL) is recognised widely as an
important health outcome in diabetes, where the daily burden of
self-management places great demands on the individual.
However, the concept of QoL remains ambiguous and poorly
deﬁned. The aim of our review was to clarify the measurement of
QoL in terms of conceptualisation, terminology and psychomet-
ric properties, to review the instruments that have been used
most frequently to assess QoL in diabetes research and make
recommendations for how to select measures appropriately.
METHODS: A systematic literature search was conducted to
identify the ten measures most frequently used to assess QoL in
diabetes research studies and clinical trials from 1995 to March
2008. RESULTS: A total of 6,085 abstracts were screened for
instrument names. An assessment of content validity indicated
that, of the ten instruments most frequently used to assess
“QoL”, only three actually do so (i.e. the generic WHOQoL, and
the diabetes-speciﬁc DQOL and ADDQoL). The remaining seven
instruments more accurately measure health status (SF-36,
EQ-5D), treatment satisfaction (DTSQ) and psychological well-
being (BDI, HADS, W-BQ, PAID). In addition, development
histories are variable, as is the extent to which psychometric
properties have been established in diabetes. CONCLUSIONS:
No single measure can suit every purpose or application but
researchers have repeatedly and erroneously used inappropriate
instruments to assess QoL in diabetes. Any conclusions related to
QoL drawn from such assessments, therefore, are fundamentally
ﬂawed. If we value QoL as a goal of therapy, then we must ensure
that the instruments we use to assess effectiveness are both valid
and reliable. Investigators need to be clear about exactly what
they wish to assess when selecting a measure (matching concept
to content) and ensure appropriate interpretation. When a holis-
tic evaluation is required, using two or three brief measures in
combination may offer a broader perspective.
PDB49
HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND
TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS
ATTENDED IN SPANISH PRIMARY CARE CENTRES
De Pablos PL1, Banegas JR2, Franch J3, Fernández S4, Díaz S4
1Hospital Universitario Dr. Negrín, Las Palmas Gran Canaria, Spain,
2Universidad Autónoma de Madrid, Madrid, Spain, 3Raval Sud Primary
Care Centre, Barcelona, Spain, 4Pﬁzer Spain, Madrid, Spain
OBJECTIVES: To assess the HRQoL and treatment satisfaction
in diabetic patients and analyze their relationship with the gly-
cemic control. METHODS: An epidemiological, cross sectional,
naturalistic study was carried out in Spanish Primary Care
centres. Patients >18 years with diabetes mellitus type 1 (T1DM)
or type 2, with insulin treatment (T2DM-i) or not (T2DM-n.i),
were enrolled in the study (consecutive cases sampling). The last
value of glycosylated hemoglobin (HbA1c) of each patient,
reported in 2006, deﬁned the glycemic control as satisfactory
(HbA1c  7%) or unsatisfactory (HbA1c > 7%). HRQoL was
obtained from EQ-5D questionnaire and its VAS subscale and TS
from the Diabetes Treatment Satisfaction Questionnaire (SATQ-
s). Differences between groups were determined by Chi-Square
and t-student tests and ANCOVA models. RESULTS: A total of
679 patients were enrolled in the study: 52.4% female; age 65.2
(13.7); BMI 28.81 (4.66); type of diabetes: 11.5% T1DM,
26.2% T2DM-i and 62.3% T2DM-n.i; mean time from diag-
noses 11.9 (9.25) years. 53% of patients achieved satisfactory
control (T1DM: 29.5%, T2DM-i: 31.5% and T2DM-n.i:
63.8%; p < 0.001). EQ-5D score were 0.76 (0.22); T1DM group
obtained a little higher score, 0.86 (0.18), than T2DM groups
(p < 0.05) and no differences were found between glycemic
control groups. VAS total score was 64.48 (17.93); patients with
satisfactory control obtained a higher score, 65.72 (17.72) vs
63.30 (18.22); p < 0.05. T1DM and T2DM-n.i groups reported
a VAS score higher than T2DM-i: 66.41 (17.90) vs. 66.28
(17.33) vs 59.47 (18.48) respectively. SATQ-s total score was
25.01 (6.67); T2DM-n.i group was more treatment-satisﬁed than
T2DM-i and T1DM: 26.15 (5.85) vs 22.97 (7.63) and 23.47
(7.10) respectively. Satisfactory control group also obtained a
higher score than unsatisfactory control group: 25.79  6.28 vs
24.39  6.88; p < 0.05. CONCLUSIONS: Patients with satisfac-
tory glycemic control obtained better values of HRQoL (VAS)
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